Bank of America Securities Reaffirms Their Hold Rating on Idexx Laboratories (IDXX)

Bank of America Securities analyst Michael Ryskin maintained a Hold rating on Idexx Laboratories today and set a price target of $790.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Ryskin is a 4-star analyst with an average return of 4.4% and a 56.20% success rate. Ryskin covers the Healthcare sector, focusing on stocks such as Charles River Labs, Illumina, and Elanco Animal Health.

In addition to Bank of America Securities, Idexx Laboratories also received a Hold from Piper Sandler’s David Westenberg in a report issued on January 22. However, on January 16, TipRanks – Google reiterated a Buy rating on Idexx Laboratories (NASDAQ: IDXX).

Based on Idexx Laboratories’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.11 billion and a net profit of $274.61 million. In comparison, last year the company earned a revenue of $975.54 million and had a net profit of $232.84 million

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IDXX in relation to earlier this year. Most recently, in November 2025, Nimrata Hunt, the EVP of IDXX sold 9,425.00 shares for a total of $6,628,983.85.